Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.40 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19559710 | 0.87 | NPC1 (0.47) | MAOBFFAR1PPARGLTA4H | |
| SCHEMBL19559666 | 0.86 | PPARG (0.46) | MAOBFFAR1PPARGLTA4H | |
| SCHEMBL19559801 | 0.82 | PPARG (0.46) | GLAMAOBPPARG | |
| SCHEMBL19559652 | 0.82 | PPARG (0.40) | MAOBFFAR1PPARGSIRT2MCL1 | |
| SCHEMBL19559762 | 0.81 | PPARG (0.45) | FFAR1PPARGPPARAPPARD | |
| SCHEMBL19559778 | 0.81 | PPARG (0.38) | GLASMN1; SMN2MAOBFFAR1PPARG | |
| SCHEMBL19559736 | 0.81 | SCN4A (0.42) | GLASMN1; SMN2MAOBFFAR1PPARG | |
| SCHEMBL19559756 | 0.80 | PPARG (0.52) | GLAFFAR1PPARG | |
| SCHEMBL19217776 | 0.80 | PPARG (0.52) | GLAFFAR1PPARG | |
| SCHEMBL6930674 | 0.79 | FFAR1 (0.61) | FFAR1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513070-B1 | PPAR-SPARING THIAZOLIDINEDIONE SALTS FOR THE TREATMENT OF METABOLIC DISEASES | CIRIUS THERAPEUTICS INC (US) | 2017-11-08 | — | — | EP | disclosed |